Erasca, Inc. ((ERAS)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Erasca, Inc. is conducting a Phase 1 clinical study titled A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors. The study aims to determine the safety and tolerability of ERAS-0015 in patients with advanced or metastatic solid tumors with specific RAS mutations, either as a standalone treatment or in combination with other therapies.
Intervention/Treatment: The study tests ERAS-0015, an oral drug, both as a monotherapy and in combination with other agents such as Keytruda and Vectibix, to evaluate its effectiveness in treating advanced solid tumors.
Study Design: This interventional study employs a non-randomized, sequential intervention model with no masking. Its primary purpose is treatment-focused, aiming to optimize dosing for ERAS-0015 alone and in combination with other drugs.
Study Timeline: The study began on May 14, 2025, with the latest update submitted on September 9, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status.
Market Implications: The successful development of ERAS-0015 could positively influence Erasca, Inc.’s stock performance, given the high demand for effective cancer treatments. This could also impact investor sentiment positively, especially if the drug shows promising results compared to competitors in the oncology sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.